Report overview
Gestational diabetes can be defined as a type of diabetes that affects pregnant women.?It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby.?However, there are possibilities that diabetes may return in the later stages of life as type II diabetes mellitus.?It is the inability of insulin to absorb the sugars consumed as part of the meal.?It may be caused due to insulin resistance in a woman s body because of increasing levels of placental hormones being produced to sustain the development of the fetus.?This condition starts when the female body is not able to make and use required amounts of insulin needed in pregnancy, resulting in a build-up of sugar in the bloodstream causing hyperglycemia.
This report aims to provide a comprehensive presentation of the global market for Gestational Diabetes Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gestational Diabetes Treatment. This report contains market size and forecasts of Gestational Diabetes Treatment in global, including the following market information:
Global Gestational Diabetes Treatment Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Gestational Diabetes Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Insulin Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Gestational Diabetes Treatment include Biocon Limited, Eli Lilly, Novo Nordisk, Boehringer Ingelheim GmbH, Sanofi S.A., Sun Pharmaceutical Industries Limited, Merck, Novartis and Adocia, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Gestational Diabetes Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gestational Diabetes Treatment Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Gestational Diabetes Treatment Market Segment Percentages, by Type, 2022 (%)
Insulin
SGLT-2 Inhibitors
Alpha-glucosidase Inhibitors
Others
Global Gestational Diabetes Treatment Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Gestational Diabetes Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Gestational Diabetes Treatment Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Gestational Diabetes Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gestational Diabetes Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gestational Diabetes Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biocon Limited
Eli Lilly
Novo Nordisk
Boehringer Ingelheim GmbH
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Merck
Novartis
Adocia
Peptron
AstraZeneca plc
Pfizer, Inc
Takeda Pharmaceutical Company Ltd
Abbott
Antares Pharma
INJEX Pharma AG
Daiichi Sankyo
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gestational Diabetes Treatment, market overview.
Chapter 2: Global Gestational Diabetes Treatment market size in revenue.
Chapter 3: Detailed analysis of Gestational Diabetes Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gestational Diabetes Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
